Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Foa

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Acta Haematologica|January 1, 1997
Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapyP Foa, A Iurlo, A Orazi, et al.
European Journal of Haematology|July 8, 1998
Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia veraP Foa, P Massaro, S Caldiera, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Biochemical modulation of fluoropyrimidines: the "GISCAD" studies. GISCAD (Italian Group for the Study of Digestive Tract Cancer)R Labianca, G Pancera, S Barni, et al.
Medical Oncology (Northwood, London, England)|May 17, 2008
Clinical analysis of multiple primary malignancies in the elderlyAndrea Luciani, G Ascione, D Marussi, et al.
Lancet (London, England)|April 11, 1981
Antiproliferative activity of cyclosporin A on human T-lymphoblastic leukaemia cell lineP Foa, A T Maiolo, L Baldini, et al.
American Journal of Hematology|March 1, 1990
1,25-Dihydroxyvitamin D3 and myeloproliferative syndromesP Foa, M Cortellaro, S Ortolani, et al.
British Journal of Haematology|October 1, 1985
Multimarker phenotypic characterization of adult and childhood acute lymphoblastic leukaemia: an Italian multicentre studyR Foà, L Baldini, G Cattoretti, et al.
Anticancer Research|January 12, 2000
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancerP Foa, M Fornier, R Miceli, et al.
American Journal of Hematology|October 27, 1997
Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant cloneP Massaro, P Foa, M Pomati, et al.
Oncology Reports|May 20, 2011
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC)E Seregni, P Foa, A Bogni, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Acta Haematologica|January 1, 1997
Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapyP Foa, A Iurlo, A Orazi, et al.
European Journal of Haematology|July 8, 1998
Long-term therapeutic efficacy and toxicity of recombinant interferon-alpha 2a in polycythaemia veraP Foa, P Massaro, S Caldiera, et al.
Advances in Experimental Medicine and Biology|January 1, 1993
Biochemical modulation of fluoropyrimidines: the "GISCAD" studies. GISCAD (Italian Group for the Study of Digestive Tract Cancer)R Labianca, G Pancera, S Barni, et al.
Medical Oncology (Northwood, London, England)|May 17, 2008
Clinical analysis of multiple primary malignancies in the elderlyAndrea Luciani, G Ascione, D Marussi, et al.
Lancet (London, England)|April 11, 1981
Antiproliferative activity of cyclosporin A on human T-lymphoblastic leukaemia cell lineP Foa, A T Maiolo, L Baldini, et al.
American Journal of Hematology|March 1, 1990
1,25-Dihydroxyvitamin D3 and myeloproliferative syndromesP Foa, M Cortellaro, S Ortolani, et al.
British Journal of Haematology|October 1, 1985
Multimarker phenotypic characterization of adult and childhood acute lymphoblastic leukaemia: an Italian multicentre studyR Foà, L Baldini, G Cattoretti, et al.
Anticancer Research|January 12, 2000
Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancerP Foa, M Fornier, R Miceli, et al.
American Journal of Hematology|October 27, 1997
Polycythemia vera treated with recombinant interferon-alpha 2a: evidence of a selective effect on the malignant cloneP Massaro, P Foa, M Pomati, et al.
Oncology Reports|May 20, 2011
Evaluation of the soluble fragments of cytokeratin 19 (CK19) in non-small cell lung cancer (NSCLC)E Seregni, P Foa, A Bogni, et al.
Pageof 9